What changed: Diffuse large B-cell lymphoma
Every dated change on the records linked to Diffuse large B-cell lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
March 2026 · 1
January 2026 · 1
2026 · 6
- 2026GuidelineDiffuse large B-cell lymphomaGuideline NCCN 2026: Advanced stage, IPI 0-1
R-CHOP × 6 (or Pola-R-CHP); consider 4 cycles plus 2 rituximab in young low-risk patients (FLYER). (NCCN Category 1)
- 2026GuidelineDiffuse large B-cell lymphomaGuideline NCCN 2026: Advanced stage, IPI 2-5
Pola-R-CHP × 6 (POLARIX) or R-CHOP × 6; tafasitamab + lenalidomide + R-CHOP (frontMIND) pending approval for IPI 3-5; DA-EPOCH-R for double-hit lymphoma; CNS prophylaxis for high CNS-IPI (contested). (NCCN Pola-R-CHP category 1 for IPI 2-5)
- 2026GuidelineDiffuse large B-cell lymphomaGuideline NCCN 2026: Primary refractory or relapse within 12 months
CD19 CAR-T (axi-cel or liso-cel) preferred over salvage chemotherapy and transplant (ZUMA-7, TRANSFORM); bridging therapy while manufacturing; bispecific ± chemotherapy if CAR-T unavailable. (NCCN Category 1 (axi-cel, liso-cel))
- 2026GuidelineDiffuse large B-cell lymphomaGuideline NCCN B-Cell Lymphomas 2026: Limited stage (I-II, non-bulky)
R-CHOP × 4 with PET-guided omission of radiation (FLYER, S1001): 4 cycles if interim PET negative; involved-site radiotherapy if PET positive. (NCCN Category 1 (R-CHOP × 4 PET-adapted for stage I-II))
- 2026Trial resultEPCORE DLBCL-1EPCORE DLBCL-1 reported
PFS HR 0.
- 2026MilestonefrontMINDfrontMIND published in Lancet; EPCORE DLBCL-1 misses OS; frontline bispecific data (EPCORE DLBCL-2) at EHA
A milestone in how this cancer is treated.
July 2025 · 2
2025 · 6
- 2025ApprovalOdronextamabOdronextamab approved in US
R/R follicular lymphoma after ≥2 lines (accelerated)
- 2025ApprovalTafasitamabTafasitamab approved in US
R/R follicular lymphoma with lenalidomide and rituximab
- 2025Trial resultfrontMINDfrontMIND reported
PFS HR 0.
- 2025Trial resultSUNMOSUNMO reported
PFS improved (HR reported 2025).
- 2025Trial resultTalicabtagene autoleucel (NexCAR19) phase 1/2Talicabtagene autoleucel (NexCAR19) phase 1/2 reported
ORR 73% (37 of 51) in relapsed or refractory B-cell malignancies; two treatment-related deaths.
- 2025MilestoneSUNMOSUNMO positive (mosun-pola); FDA rejects STARGLO indication over applicability; POLARIX 5-year data
A milestone in how this cancer is treated.
August 2024 · 1
March 2024 · 1
January 2024 · 1
2024 · 4
- 2024ApprovalEpcoritamabEpcoritamab approved in US
Relapsed/refractory follicular lymphoma after ≥2 lines (accelerated; full 2025 with R2)
- 2024ApprovalOdronextamabOdronextamab approved in EU
R/R DLBCL and follicular lymphoma after ≥2 lines (conditional)
- 2024Trial resultSTARGLOSTARGLO reported
OS HR 0.
- 2024MilestoneSTARGLOSTARGLO shows OS benefit for glofitamab-GemOx; odronextamab approved in EU
A milestone in how this cancer is treated.
July 2023 · 1
June 2023 · 1
May 2023 · 1
April 2023 · 1
2023 · 6
- 2023ApprovalEpcoritamabEpcoritamab approved in EU
EU brand Tepkinly
- 2023ApprovalEpcoritamabEpcoritamab approved in US
Relapsed/refractory DLBCL or high-grade B-cell lymphoma after ≥2 lines (accelerated)
- 2023ApprovalGlofitamabGlofitamab approved in US
Relapsed/refractory DLBCL after ≥2 lines (accelerated)
- 2023ApprovalPolatuzumab vedotinPolatuzumab vedotin approved in US
Untreated DLBCL, IPI ≥2, with R-CHP (Pola-R-CHP)
- 2023MilestoneGlofitamabGlofitamab and epcoritamab approved: off-the-shelf T-cell redirection
A milestone in how this cancer is treated.
- 2023MilestoneGlofitamabGlofitamab, epcoritamab approved
A milestone in how this cancer is treated.
December 2022 · 1
April 2022 · 1
2022 · 7
- 2022ApprovalAxicabtagene ciloleucelAxicabtagene ciloleucel approved in US
Second-line LBCL refractory or relapsed within 12 months
- 2022ApprovalLoncastuximab tesirineLoncastuximab tesirine approved in EU
R/R DLBCL ≥2 lines (conditional)
- 2022ApprovalMosunetuzumabMosunetuzumab approved in US
R/R follicular lymphoma after ≥2 lines (accelerated)
- 2022Trial resultEPCORE NHL-1EPCORE NHL-1 reported
ORR 63%, CR 39%.
- 2022Trial resultTRANSFORMTRANSFORM reported
EFS HR 0.
- 2022MilestonePOLARIXPOLARIX: first frontline improvement on R-CHOP in twenty years; CAR-T approved second line
A milestone in how this cancer is treated.
- 2022MilestoneDiffuse large B-cell lymphomaZUMA-7: CAR-T beats transplant
A milestone in how this cancer is treated.
April 2021 · 1
March 2021 · 1
2021 · 8
- 2021ApprovalLoncastuximab tesirineLoncastuximab tesirine approved in US
Relapsed/refractory DLBCL after ≥2 systemic therapies
- 2021ApprovalTafasitamabTafasitamab approved in EU
EU brand Minjuvi
- 2021Trial resultBELINDABELINDA reported
EFS HR 1.
- 2021Trial resultLOTIS-2LOTIS-2 reported
ORR 48%, CR 24%.
- 2021Trial resultPOLARIXPOLARIX reported
2-year PFS 76.
- 2021Trial resultRELIANCERELIANCE reported
ORR 75.
- 2021Trial resultZUMA-7ZUMA-7 reported
EFS HR 0.
- 2021MilestoneLoncastuximab tesirineLoncastuximab tesirine approved; BELINDA fails while ZUMA-7 and TRANSFORM succeed
A milestone in how this cancer is treated.
July 2020 · 1
2020 · 5
- 2020ApprovalSelinexorSelinexor approved in US
Relapsed/refractory DLBCL; myeloma with bortezomib after ≥1 line
- 2020ApprovalTafasitamabTafasitamab approved in US
R/R DLBCL with lenalidomide, transplant-ineligible (accelerated)
- 2020Trial resultInter-B-NHL Ritux 2010Inter-B-NHL Ritux 2010 reported
3-year EFS 93.
- 2020Trial resultL-MINDL-MIND reported
ORR 60%, CR 43%.
- 2020MilestoneTafasitamabTafasitamab-lenalidomide (L-MIND) approved for transplant-ineligible relapse
A milestone in how this cancer is treated.
June 2019 · 1
2019 · 2
2018 · 1
October 2017 · 1
2017 · 3
- 2017ApprovalAxicabtagene ciloleucelAxicabtagene ciloleucel approved in US
Relapsed/refractory large B-cell lymphoma ≥2 lines
- 2017MilestoneAxicabtagene ciloleucelAxi-cel CAR-T approved
A milestone in how this cancer is treated.
- 2017MilestoneAxicabtagene ciloleucelAxi-cel: first CAR-T approved for large B-cell lymphoma (ZUMA-1)
A milestone in how this cancer is treated.